Why clinicians and investors are watching Mirum Pharmaceuticals after its EASL 2026 update
Find out how Mirum Pharmaceuticals’ EASL 2026 data could reshape rare liver disease treatment and investor sentiment.
Can volixibat and brelovitug expand Mirum Pharmaceuticals’ rare liver disease ambitions?
Mirum Pharmaceuticals’ EASL 2026 data deepen its rare liver disease strategy. Find out what changes for PSC, HDV and PFIC care.
What Mirum’s Bluejay acquisition reveals about its long-term liver disease strategy
Mirum adds brelovitug in HDV through Bluejay deal. See how this could redefine rare liver disease leadership ahead of AZURE Phase 3 results in 2026.